Oxytocin receptors (OTR) have been described in a number of tumours of different origin, and represent a new target for specific radiolabelled oxytocin (OT) analogues in cancer diagnosis and therapy. By linking the DOTA chelating agent to position 8 of the deamino derivative of Lys 8-vasotocin (dLVT), we obtained a new compound (DOTA-dLVT) with the following characteristics: (I) it forms a monomeric and stable compound that binds to OTR with an affinity comparable to that of the endogenous OT ligand; (2) it is characterised by a very good selectivity profile for the human OTR, with a low affinity binding to the closely related Via, VIb and V2 vasopressin receptor subtypes; (3) it induces rapid and persistent receptor intemalisation and (4) when radiolabelled, [111In]-DOTA-dLVT is efficiently and selectively taken up by OTR-positive tumours grown in mice. These features makes radiolabelled DOTA-dLVT a very good candidate for the radiotargeting of OTR-expressing tumours. © 2003 Cancer Research UK.

Improved radiotracing of oxytocin receptor-expressing tumours using the new [111 In]-DOTA-Lys8-deamino-vasotocin analogue

Chinol, M.;Paganelli, G.;
2003

Abstract

Oxytocin receptors (OTR) have been described in a number of tumours of different origin, and represent a new target for specific radiolabelled oxytocin (OT) analogues in cancer diagnosis and therapy. By linking the DOTA chelating agent to position 8 of the deamino derivative of Lys 8-vasotocin (dLVT), we obtained a new compound (DOTA-dLVT) with the following characteristics: (I) it forms a monomeric and stable compound that binds to OTR with an affinity comparable to that of the endogenous OT ligand; (2) it is characterised by a very good selectivity profile for the human OTR, with a low affinity binding to the closely related Via, VIb and V2 vasopressin receptor subtypes; (3) it induces rapid and persistent receptor intemalisation and (4) when radiolabelled, [111In]-DOTA-dLVT is efficiently and selectively taken up by OTR-positive tumours grown in mice. These features makes radiolabelled DOTA-dLVT a very good candidate for the radiotargeting of OTR-expressing tumours. © 2003 Cancer Research UK.
2003
Chini, B.; Chinol, M.; Cassoni, P.; Papi, S.; Reversi, A.; Areces, L.; Marrocco, T.; Paganelli, G.; Manning, M.; Bussolati, G.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2496236
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 30
social impact